CSPC Pharmaceutical Group (01093): Phase III clinical trial of JMT101 combined with osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations achieves positive topline results
Zhito Finance APP News, CSPC Pharmaceutical Group (01093) announced that the Phase III clinical trial of becotatug (JMT101) developed by the group in combination with osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutation (EGFR ex20ins) has met the primary endpoint in a prespecified interim analysis, achieving positive topline results. Compared with platinum-based chemotherapy combined with pemetrexed, the treatment regimen of this product combined with osimertinib significantly prolonged patients' progression-free survival (PFS) and showed a trend of overall survival (OS) benefit.
Latest
47 m ago

